Delving into the Latest Updates on Catalent Greenville, Inc. with Synapse

Overview

Tags

Other Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

No Data

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

DAT x NET x α-adrenergic receptor	1

Primary objective: To evaluate the pharmacokinetic (PK) characteristics of a single dose of 5 mg lasofoxifene tablets in healthy Chinese female adult subjects. Secondary objective: To evaluate the safety and tolerability of a single dose of 5 mg lasofoxifene tablets in healthy Chinese female adult subjects.

Start Date05 Nov 2024

Sponsor / Collaborator

Shanghai Henlius Biotech, Inc.

[+1]

CTR20242519

/ RecruitingPhase 3

一项比较阿贝西利联合拉索昔芬或氟维司群用于雌激素受体阳性（ER+）、人表皮生长因子受体2阴性（HER2-）、雌激素受体1（ESR1）突变的绝经前/后女性和男性局部晚期或转移性乳腺癌患者的有效性和安全性的开放标签、随机、多中心研究

[Translation] An open-label, randomized, multicenter study comparing the efficacy and safety of abemaciclib combined with lasofoxifene or fulvestrant in premenopausal and postmenopausal women and men with locally advanced or metastatic breast cancer who are estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-), and have an estrogen receptor 1 (ESR1) mutation

针对既往接受过瑞波西利或哌柏西利治疗、ER+、HER2-、ESR1突变的绝经前/后女性和男性局部晚期或转移性乳腺癌患者，评估分别使用阿贝西利联合拉索昔芬或氟维司群治疗的无进展生存期（PFS）情况。

[Translation]

To evaluate the progression-free survival (PFS) of abemaciclib combined with lasofoxifene or fulvestrant in premenopausal/postmenopausal women and men with locally advanced or metastatic breast cancer who were ER+, HER2-, and ESR1 mutated and had received prior treatment with ribociclib or palbociclib.

Start Date29 Oct 2024

Sponsor / Collaborator

Shanghai Henlius Biotech, Inc.

[+1]

CTR20242627

/ RecruitingPhase 3

一项在羟基脲缓解不佳或不耐受的原发性血小板增多症受试者中评价Bomedemstat（MK-3543/IMG-7289）与最佳可用治疗（BAT）相比的安全性和有效性的Ⅲ期、随机、开放性、活性药物对照临床研究

[Translation] A Phase III, randomized, open-label, active-controlled clinical study to evaluate the safety and efficacy of Bomedemstat (MK-3543/IMG-7289) compared with best available therapy (BAT) in subjects with essential thrombocythemia who were inadequately responded to or intolerant of hydroxyurea

在羟基脲缓解不佳或不耐受的原发性血小板增多症受试者中评价Bomedemstat（MK-3543/IMG-7289）与最佳可用治疗（BAT）相比的安全性和有效性

[Translation]

To evaluate the safety and efficacy of Bomedemstat (MK-3543/IMG-7289) compared with best available therapy (BAT) in subjects with essential thrombocythemia who are inadequately responded to or intolerant of hydroxyurea

Start Date26 Sep 2024

Sponsor / Collaborator

MSD R&D (China) Co. Ltd.

[+2]

100 Clinical Results associated with Catalent Greenville, Inc.

Login to view more data

0 Patents (Medical) associated with Catalent Greenville, Inc.

Login to view more data

100 Deals associated with Catalent Greenville, Inc.

Login to view more data

100 Translational Medicine associated with Catalent Greenville, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 10 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3 Clinical

1

Login to view more data